PureTech Health plc (OTCMKTS:PTCHF – Get Free Report) was up 22.6% during trading on Thursday . The stock traded as high as $1.90 and last traded at $1.90. Approximately 11,000 shares traded hands during trading, an increase of 39% from the average daily volume of 7,916 shares. The stock had previously closed at $1.55.
PureTech Health Price Performance
The firm’s fifty day moving average is $1.67 and its 200-day moving average is $1.68.
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Read More
- Five stocks we like better than PureTech Health
- What is the Australian Securities Exchange (ASX)
- General Dynamics Hits New Highs: Why It Might Keep Climbing
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Nike’s Turnaround: If the Shoe Fits, Buy It!
- 5 discounted opportunities for dividend growth investors
- NVIDIA Breaks Out to New Highs: What Comes Next?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png&h=45&w=95&zc=2){kind=logo}
